Is Drug Pricing Backlash a Serious Risk for Big Pharma Stocks?

Is Drug Pricing Backlash a Serious Risk for Big Pharma Stocks?

The sole way that backlash over drug prices would dent pharma stock prices is from policy change, whether it's through new laws or changes to the U.S. regulatory landscape. Congressional researchers assembled a substantial set of reports that document how drug price increases were handled at each of the companies whose CEOs were scheduled to testify, and the findings were very illuminating.